[go: up one dir, main page]

MA39027B1 - Pyrido[4,3-b]pyrazine-2-carboxamides utilisées en tant qu'agents neurogènes dans le traitement des troubles neurodégénératifs - Google Patents

Pyrido[4,3-b]pyrazine-2-carboxamides utilisées en tant qu'agents neurogènes dans le traitement des troubles neurodégénératifs

Info

Publication number
MA39027B1
MA39027B1 MA39027A MA39027A MA39027B1 MA 39027 B1 MA39027 B1 MA 39027B1 MA 39027 A MA39027 A MA 39027A MA 39027 A MA39027 A MA 39027A MA 39027 B1 MA39027 B1 MA 39027B1
Authority
MA
Morocco
Prior art keywords
pyrido
pyrazine
treatment
neurodegenerative disorders
neurogenic agents
Prior art date
Application number
MA39027A
Other languages
English (en)
Other versions
MA39027A1 (fr
Inventor
Ravi Jagasia
Roland Jakob-Roetne
Juergen Wichmann
Jens-Uwe Peters
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA39027A1 publication Critical patent/MA39027A1/fr
Publication of MA39027B1 publication Critical patent/MA39027B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)

Abstract

L'invention concerne des composés de formule générale (i), dans laquelle r
MA39027A 2013-11-12 2014-11-07 Pyrido[4,3-b]pyrazine-2-carboxamides utilisées en tant qu'agents neurogènes dans le traitement des troubles neurodégénératifs MA39027B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13192406 2013-11-12
PCT/EP2014/073988 WO2015071178A1 (fr) 2013-11-12 2014-11-07 Pyrido[4,3-b]pyrazine-2-carboxamides utilisées en tant qu'agents neurogènes dans le traitement des troubles neurodégénératifs

Publications (2)

Publication Number Publication Date
MA39027A1 MA39027A1 (fr) 2018-05-31
MA39027B1 true MA39027B1 (fr) 2018-10-31

Family

ID=49552255

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39027A MA39027B1 (fr) 2013-11-12 2014-11-07 Pyrido[4,3-b]pyrazine-2-carboxamides utilisées en tant qu'agents neurogènes dans le traitement des troubles neurodégénératifs

Country Status (17)

Country Link
US (1) US9670206B2 (fr)
EP (1) EP3068781B1 (fr)
JP (1) JP6229056B2 (fr)
KR (1) KR101861937B1 (fr)
CN (1) CN105764901B (fr)
AU (1) AU2014350371B2 (fr)
CA (1) CA2929461A1 (fr)
CL (1) CL2016001024A1 (fr)
CR (1) CR20160142A (fr)
EA (1) EA028940B1 (fr)
IL (1) IL244619A0 (fr)
MA (1) MA39027B1 (fr)
MX (1) MX2016006052A (fr)
PE (1) PE20160692A1 (fr)
PH (1) PH12016500605A1 (fr)
UA (1) UA117041C2 (fr)
WO (1) WO2015071178A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018119344A (ru) 2015-10-26 2019-11-28 Байер Кропсайенс Акциенгезельшафт Конденсированные бициклические гетероциклические производные в качестве средства для борьбы с вредителями
US20210300940A1 (en) * 2018-07-31 2021-09-30 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
EP3931192B1 (fr) 2019-02-26 2024-03-20 Bayer Aktiengesellschaft Dérivés d'hétérocyclène bicycliques condensés en tant que pesticides
KR20210133240A (ko) 2019-02-26 2021-11-05 바이엘 악티엔게젤샤프트 살충제로서의 융합된 비시클릭 헤테로사이클 유도체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773834A2 (fr) * 2004-08-03 2007-04-18 Serenex, Inc. Derives de naphthyridine 2, 8-disubstitues
CN101356173B (zh) * 2005-11-11 2012-10-31 阿特纳赞塔里斯有限公司 新的吡啶并吡嗪和它们作为激酶调节剂的用途
CN102414180A (zh) * 2009-03-02 2012-04-11 西特里斯药业公司 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物
JP5649644B2 (ja) * 2009-04-22 2015-01-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド
JP6126528B2 (ja) * 2010-07-07 2017-05-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ 神経新生促進化合物
RU2673549C2 (ru) * 2013-05-03 2018-11-28 Ф. Хоффманн-Ля Рош Аг Производные изохинолина, стимулирующие нейрогенез
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物

Also Published As

Publication number Publication date
JP2016536320A (ja) 2016-11-24
UA117041C2 (uk) 2018-06-11
CL2016001024A1 (es) 2016-11-18
CA2929461A1 (fr) 2015-05-21
CR20160142A (es) 2016-05-04
PH12016500605A1 (en) 2016-06-13
EP3068781A1 (fr) 2016-09-21
WO2015071178A1 (fr) 2015-05-21
PE20160692A1 (es) 2016-07-28
EA028940B1 (ru) 2018-01-31
US9670206B2 (en) 2017-06-06
EA201690971A1 (ru) 2016-08-31
IL244619A0 (en) 2016-04-21
KR101861937B1 (ko) 2018-05-28
MA39027A1 (fr) 2018-05-31
JP6229056B2 (ja) 2017-11-08
US20160251355A1 (en) 2016-09-01
KR20160061427A (ko) 2016-05-31
CN105764901B (zh) 2018-06-22
MX2016006052A (es) 2016-07-18
CN105764901A (zh) 2016-07-13
EP3068781B1 (fr) 2017-12-20
AU2014350371B2 (en) 2018-02-15
HK1223916A1 (zh) 2017-08-11

Similar Documents

Publication Publication Date Title
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
MA37943B1 (fr) 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc
MA40706A1 (fr) Pyrrolopyrimidines et pyrazolopyrimidines utilisées en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7
MA35049B1 (fr) Triazolopyridines
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
MA35926B1 (fr) Pyrrolidine-2-carboxamides substitués
MA38922A3 (fr) Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
EP2828247A4 (fr) Composés pour le traitement de l'amyotrophie spinale
EP2819519A4 (fr) Composés pour le traitement de l'amyotrophie spinale
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
EP2871957A4 (fr) Composés macrocycliques en tant qu'inhibiteurs de l'intégrase du vih
MA37866A1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
GEP201706659B (en) Novel bicyclic pyridinones
IN2014MN00697A (fr)
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
EP2877469A4 (fr) Dérivés de naphthyridinedione substitués en tant qu'inhibiteurs de l'intégrase du vih
WO2012104823A3 (fr) Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives
MA34578B1 (fr) Composés de tétrahydrofuranyl disubstitués en tant qu'antagonistes du récepteur de la bradykinine b1
MA39027A1 (fr) Pyrido[4,3-b]pyrazine-2-carboxamides utilisées en tant qu'agents neurogènes dans le traitement des troubles neurodégénératifs
MA35742B1 (fr) Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques
MA20150280A2 (fr) Dérivés d'aryléthynyle
PH12016501764B1 (en) Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
MA38010B1 (fr) Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5